The impact of direct-to-consumer advertised drugs on drug sales in the US and New Zealand

Applied Health Economics and Health Policy

Volumn 6, Issue 2-3, 2008, Pages 93-102

  Norey, Edward ^a   Simone, Tessa M ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; ESOMEPRAZOLE; ESZOPICLONE; EZETIMIBE PLUS SIMVASTATIN; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; OMEPRAZOLE; OXIS TURBUHALER; ROFECOXIB; ROSUVASTATIN; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

BUDGET; CONSUMER; DRUG COST; DRUG MARKETING; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MEDICAID; MEDICARE; NEW ZEALAND; PRESCRIPTION; REVIEW; UNITED STATES;

ADULT; ADVERTISING AS TOPIC; AGED; BUDGETS; COMMERCE; CONSUMER PARTICIPATION; DELIVERY OF HEALTH CARE; DRUG COSTS; DRUG INDUSTRY; DRUG PRESCRIPTIONS; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INSURANCE, HEALTH; MEDICARE; MIDDLE AGED; NEW ZEALAND; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 60749096355     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200806020-00002     Document Type: Review

References (36)

1. Stange KC. Time to ban direct-to-consumer prescription drug marketing. Ann Fam Med 2007 Mar-Apr; 5 (2): 101-4
2. Kaiser Family Foundation. Impact of direct-to-consumer advertising on prescription drug spending. 2003 [online]. Available from URL: http://www.kff.org/rxdrugs/upload/Impact-of-Direct-to-Consumer-Advertising-on- Prescription-Drug-Spending-Summary-of-Findings.pdf [Accessed 2008 Jan 15]
3. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005 Apr 27; 293 (16): 1995-2002
4. Mintez B, Barer ML, Kravitz RL, et al. How does direct-toconsumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ 2003; 169: 405-12
5. Kravitz RL. Direct-to-consumer advertising of prescription drugs. West J Med 2000 Oct; 173 (4): 221-2
6. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989 Apr; 82 (4): 203-5
7. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995 Oct; 108 (4): 978-81
8. Lethen H, Flachskampf FA, Schneider R, et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol 1997 Oct 15; 80 (8): 1066-9
9. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999 Sep 9; 341 (11): 793-800
10. Botteman MF, Caprini J, Stephens JM, et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther 2002 Nov; 24 (11): 1960-86; discussion 38
11. OECD. Health-at-a-glance 2007: OECD indicators, health expenditures per capita. 2007 [online]. Available from URL: http://miranda.sourceoecd.org/vl= 1650080/cl=12/nw=1/rpsv/health2007/5-1.htm [Accessed 2008 Jan 15]
12. OECD. Health-at-a-glance 2007: OECD indicators, pharmaceutical expenditures. 2007 [online]. Available from URL: http://miranda.sourceoecd.org/ vl=1650080/cl=12/nw=1/rpsv/health2007/5-4.htm [Accessed 2008 Jan 15]
13. The Commonwealth Fund. The Commonwealth Fund Symposium on Healthcare Policy. Descriptions of healthcare systems: Australia, Canada, Germany, the Netherlands, New Zealand, the United Kingdom, and the United States. 2006 [online]. Available from URL: http://www.commonwealthfund.org/usr-doc/2006- ItlSymposium-Country-Profiles2.doc?section=4059 [Accessed 2008 Jan 15]
14. Kaiser Family Foundation. Health care costs: a primer. 2007 Aug [online]. Available from URL: http://www.kff.org/insurance/upload/7670.pdf [Accessed 2008 Jan 15]
15. PHARMAC. About PHARMAC [online]. Available from URL: http://www.pharmac. govt.nz/who-are-pharmac.asp [Accessed 2008 Jan 15]
16. Coney S. Direct-to-consumer advertising of prescription pharmaceuticals: a consumer perspective from New Zealand. J Public Policy Marketing 2002; 21 (2): 213-23
17. PHARMAC. Annual review 2001 [online]. Available from URL: http://www.pharmac.govt.nz/2001/10/01/AnnRvw2001.pdf [Accessed 2008 Jan 15]
18. PHARMAC. Annual review 2002 [online]. Available from URL: http://www.pharmac.govt.nz/2002/11/04/AR02.pdf [Accessed 2008 Jan 15]
19. PHARMAC. Annual report 2001-2007 [online]. Available from URL: http://www.pharmac.govt.nz/annual-report.asp [Accessed 2008 Jan 15]
20. PHARMAC. Annual review 2007 [online]. Available from URL: http://www.pharmac.govt.nz/annual-review.asp [Accessed 2008 Jan 15]
21. TNS New Zealand. Access to medicines, general public and medical practitioner survey, market research report 2004 [online]. Available from URL: http://www.rmianz.co.nz/pdfs/tnsresearchdec04.pdf [Accessed 2008 Jan 15]
22. Frizelle F. Are we spending enough on healthcare in New Zealand? NZ Med J 2003 Feb 21; 116 (1169): U324
23. Gellad ZF, Lyles KW. Direct-to-consumer advertising of pharmaceuticals. Am J Med 2007 Jun; 120 (6): 475-80
24. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007 Aug 16; 357 (7): 673-81
25. IMS Health. Top 10 therapeutic classes by U.S. sales. 2007 [online]. Available from URL: http://www.imshealth.com/ims/portal/front/articleC/0,2777, 6599-80408854-80411855,00.html [Accessed 2008 Jan 15]
26. IMS Health. Top 10 therapeutic classes by U.S. dispensed prescription. 2007 [online]. Available from URL: http://www.imshealth.com/ims/portal/front/ articleC/0,2777,6599-80411808-80413635,00.html [Accessed 2008 Jan 15]
27. IMS Health. Top 10 products by U.S. dispensed prescription. 2007 [online]. Available from URL: http://www.imshealth.com/ims/portal/front/ articleC/0,n2777,6599-80411799-80413615,00.html [Accessed 2008 Jan 15]
28. IMS Health. Top products by U.S. sales. 2007 [online]. Available from URL: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599-80408845- 80411835,00.html [Accessed 2008 Jan 15]
29. Sepracor Inc. 2006 annual report. 2006 [online]. Available from URL: http://media.corporate-ir.net/media-files/irol/90/90106/SEPR06AR.pdf [Accessed 2008 Jan 15]
30. Sepracor Inc. Form 10-K/A Sepracor Inc/DE/-SEPR. 2007 [online]. Available from URL: http://library.corporate-ir.net/library/90/901/90106/items/240973/ SEPRACORINCDE10KA.pdf [Accessed 2008 Jan 15]
31. The danger in sleeping pill advertisements: reading between the lines [editorial]. ProHealth, 2006 Nov 29 [online]. Available from URL: http://www.immunesupport.com/library/showarticle.cfm/ID/7537 [Accessed 2008 Jan 15]
32. Novice Investing. Mark your calendar for Merck. 2005 [online]. Available from URL: http://www.noviceinvesting.com/MRK2.php [Accessed 2008 Jan 15]
33. AstraZeneca. 2005 annual report [online]. Available from URL: http://www.astrazeneca.com/sites/7/imagebank/typeArticleparam511672/ astrazeneca-2005-annual-review.pdf [Accessed 2008 Jan 15]
34. Levine S, Campen D, Millares M, et al. Kaiser Permanente's prescription drug benefit. Health Aff (Millwood) 2000 Mar-Apr; 19 (2): 185-90
35. Kaiser Permanente. 2004 annual report. Oakland (CA); Kaiser Permanente, 2004
36. Kaiser Permanente. 2004 financial statement. Oakland (CA): Kaiser Permanente, 2004